Citigroup Maintains Neutral on Intellia Therapeutics, Lowers Price Target to $29
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Lebowitz has maintained a Neutral rating on Intellia Therapeutics (NTLA) and reduced the price target from $31 to $29.

May 10, 2024 | 9:34 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Citigroup's adjustment of the price target for Intellia Therapeutics reflects a cautious but not pessimistic outlook, potentially influencing investor sentiment.
The reduction in price target by a major financial institution like Citigroup, while maintaining a neutral stance, suggests a recalibration of expectations rather than a fundamental shift in the company's outlook. This adjustment is likely to have a moderate impact on investor sentiment in the short term, as it reflects a more cautious valuation without signaling a significant downgrade in the company's prospects.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90